Astex targets CNS with fragment-based approach

Building on success in the oncology field, Astex Pharmaceuticals is applying its fragment based drug discovery (FBDD) platform to new neurodegenerative disease targets.

Oct 25, 2016
Page of

Astex Pharmaceuticals

Astex is a leader in innovative drug discovery and development, committed to the fight against cancer and diseases of the central nervous system.

No comments yet.